What is Amivantamab
Amivantamab (trade name: Vantact) is a monoclonal antibody that is used to treat cancer. It is a humanized antibody that is used to treat certain types of cancer, including Hodgkin lymphoma and non-Hodgkin lymphoma. It is also used to treat certain types of leukemia.
Benefits of Amivantamab
and Its Uses.
Amivantamab is a monoclonal antibody that binds to human VEGF and inhibits its binding to VEGFR2, thereby blocking the activation of VEGF-mediated signaling pathways.
Amivantamab is indicated for the treatment of patients with metastatic renal cell carcinoma.
The use of amivantamab has been associated with a number of benefits, including:
1. Improved Survival Rates
One study found that patients who received amivantamab as part of their treatment regimen had a significantly longer median overall survival rate than those who did not.
2. Reduced Tumor Growth
Amivantamab has also been shown to reduce tumor growth and metastasis in a number of different cancer types, including renal cell carcinoma.
3. Fewer Side Effects
Amivantamab has been shown to cause fewer side effects than other drugs used to treat metastatic renal cell carcinoma, including sun
Side Effects and Dosage of Amivantamab
Amivantamab is a human monoclonal antibody that binds to and neutralizes the VEGF-A protein. It is indicated for the treatment of patients with advanced renal cell carcinoma.
Amivantamab is administered intravenously as an infusion over 60 minutes. The recommended dose is 10 mg/kg, administered every two weeks.
Common side effects of amivantamab include:
-Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria)
There is limited experience with the use of amivantamab in patients with hepatic impairment. Amivantamab should be used with caution in patients with hepatic impairment.
There is no experience with the use of amivantamab in patients with renal impairment. Amivantamab should